Shire Licenses Parion’s P-321 for Dry Eye Disease

May 12, 2017: By Joan McKenna

ShireShire has signed an exclusive global licensing agreement to develop and commercialize Parion Sciences’ P-321 for dry eye disease in adults, the two companies announced May 1.

P-321 is an epithelial sodium channel (ENaC) inhibitor in Phase II development as a topical treatment to address tear volume deficiency and promote ocular surface healing.

Shire will make an initial $20 million up-front payment, plus a potential near-term milestone payment of $20 million, to lead development of P-321.

Parion is entitled to additional milestone payments, and the deal has a potential total value of $535 million.

Parion, of Durham, NC, has the option to co-fund development through later stages in exchange for royalties. In addition, Parion has the option to co-fund and benefit from commercialization.

Shire, headquartered in Dublin, launched Xiidra for dry eye disease—its first ophthalmic product—in August 2016.

 

Need Deeper Analysis? Sign up for Market Scope's monthly newsletter to get in-depth coverage of the ophthalmic market, including quarterly procedure volumes based on survey data and meeting coverage from around the world.

Recent Ophthalmic News

US Health Secretary Alex Azar Takes Aim at Rebates in US Senate Hearing

Beyeonics Surgical Raises $11.5 Million in Initial Funding Round

MeiraGTx Raises $75 Million in Initial Public Offering

GenSight to Pursue Approval for LHON Gene Therapy Candidate, Despite Phase III Setback

Optovue Receives FDA Clearance for AngioAnalytics, First OCT Angiography Metrics

Nexy Robotic Retinal Imaging System Receives FDA Clearance

Ocutrx Receives US Patent for Oculenz AR Glasses for Macular Degeneration

Allergan’s Bimatoprost SR Demonstrates Noninferiority to Timolol in Phase III Glaucoma Study

KKR to acquire Envision Healthcare, Including Amsurg ASC Business

Ophthalmologist Carmen Puliafito, MD, Seeks to Regain Medical License

Avedro Gains J Code for Photrexa Formulations in Preliminary CMS Decision

EyeGate Seeks to Study Ocular Bandage Gel in Punctate Epitheliopathy

Nicox, Ironwood to Collaborate on Novel Ophthalmic Treatments

US FDA Approves MDGH’s Moxidectin for Treatment of River Blindness

Bausch + Lomb Enrolls First Patient in Trial for enVista MX60EF Trifocal IOL

Cincinnati Eye Institute Partners with Private Equity Firm to Pursue National Expansion

Ophthotech Enters Gene Therapy Deals with University of Florida, University of Pennsylvania

Teva’s Launches Generic Version of Restasis in Canada

Clearside’s Phase II Trial for DME Candidate Meets Primary Endpoint

Orasis Raises $13 Million in Series B Financing

Coming soon

2018 Optical Coherence Tomography Report: A Global Market Analysis for 2017 to 2023